Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Craddock

Showing results (1-10 of 165) with videos related to

Pageof 17
Sort By:
Cytotherapy|March 8, 2011
Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignanciesCharles Craddock
Hematology. American Society of Hematology. Education Program|December 10, 2013
Pharmacological methods to reduce disease recurrenceCharles Craddock
Hematology. American Society of Hematology. Education Program|December 9, 2022
Transplant in AML with measurable residual disease: proceed or defer?Charles Craddock
British Journal of Haematology|November 15, 2020
Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and futureCharles Craddock
Clinical Medicine (London, England)|January 16, 2008
Molecularly targeted therapy in myeloid leukaemiasCharles Craddock
The Lancet. Haematology|March 19, 2018
Conditioning intensity in HCT for AML: the jury is still outCharles Craddock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Improving Outcomes in High-Risk Myelodysplasia: Festina LenteCharles Craddock
Haematologica|July 1, 2026
A potent and manipulable graft-<i>versus</i>-leukemia effect underpins the increasingly important role of transplantation in acute myeloid leukemiaCharles Craddock
British Journal of Haematology|November 15, 2020
Bone marrow transplantation in the United Kingdom - past, present and futureJohn Barrett, Charles Craddock
Current Opinion in Hematology|December 27, 2018
Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?Charles Craddock, Manoj Raghavan
Pageof 17

Showing results (1-10 of 165) with videos related to

Sort By:
Pageof 17
Cytotherapy|March 8, 2011
Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignanciesCharles Craddock
Hematology. American Society of Hematology. Education Program|December 10, 2013
Pharmacological methods to reduce disease recurrenceCharles Craddock
Hematology. American Society of Hematology. Education Program|December 9, 2022
Transplant in AML with measurable residual disease: proceed or defer?Charles Craddock
British Journal of Haematology|November 15, 2020
Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and futureCharles Craddock
Clinical Medicine (London, England)|January 16, 2008
Molecularly targeted therapy in myeloid leukaemiasCharles Craddock
The Lancet. Haematology|March 19, 2018
Conditioning intensity in HCT for AML: the jury is still outCharles Craddock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Improving Outcomes in High-Risk Myelodysplasia: Festina LenteCharles Craddock
Haematologica|July 1, 2026
A potent and manipulable graft-<i>versus</i>-leukemia effect underpins the increasingly important role of transplantation in acute myeloid leukemiaCharles Craddock
British Journal of Haematology|November 15, 2020
Bone marrow transplantation in the United Kingdom - past, present and futureJohn Barrett, Charles Craddock
Current Opinion in Hematology|December 27, 2018
Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?Charles Craddock, Manoj Raghavan
Pageof 17